Pfizer Inks $325 Million Deal to Exit Neurontin Class Action
After a failed bid by Quinn Emanuel for help from the U.S. Supreme Court, Pfizer opted to settle claims over the company's marketing of its epilepsy drug.
By Ross Todd|June 02, 2014
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
This premium content is locked for Litigation Daily subscribers only.
Subscribe now to enjoy unlimited access to Litigation Daily content,
5 free articles* across the ALM Network every 30 days,
Exclusive access to other free ALM publications
And exclusive discounts on ALM events and publications.
*May exclude premium content Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to email@example.com to learn more.
As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters.
Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss.
Tailored just for you. In your inbox. Every day.